Experience

Panolos Bioscience

• South Korea
• Biotechnology Research
• 1 - 100 Employee

• Chief Executive Officer

  • Sep 2019 - Present

  We create Bi-,Multi-specific Biotherapeutics Platform for the development of novel therapeutic concepts We create Bi-,Multi-specific Biotherapeutics Platform for the development of novel therapeutic concepts



FiveElements Partners Inc.

• 대한민국 서울

• Chief Executive Officer

  • Jan 2019 - Dec 2021

  As a biotech company builder, we initially discovered two startups in Korea and one startup in the US and supported investment up to Series A. As a biotech company builder, we initially discovered two startups in Korea and one startup in the US and supported investment up to Series A.



PineThera, Inc.

• 대한민국 서울 송파구

• Chief Executive Officer

  • Jun 2018 - Jan 2019

  Realize your inspiration for the patients Realize your inspiration for the patients



GI INNOVATION

• South Korea
• Biotechnology Research
• 1 - 100 Employee

• Chief Research & Business Development Officer

  • Aug 2018 - Dec 2018

  Structural engineering & design of protein therapeutics (GI-101, GI-301). Signed a CDMO contract with Samsung Biologics for GI101, a bispecific anti-cancer drug, and led process development. Support for JV establishment of each GI cell and GI biome. Structural engineering & design of protein therapeutics (GI-101, GI-301). Signed a CDMO contract with Samsung Biologics for GI101, a bispecific anti-cancer drug, and led process development. Support for JV establishment of each GI cell and GI biome.



Progen

• 대한민국 경기도 성남

• Principal Scientist

  • Jun 2017 - Apr 2018

  New drug development for Metabolic and allergic diseases New drug development for Metabolic and allergic diseases



Genexine, Inc.

• South Korea
• Biotechnology Research
• 1 - 100 Employee

• Senior Research Scientist

  • Apr 2011 - May 2017

  DSP Team manager Project leader for GX-F7 (Factor VII-hyFc) and metabolic disease (bi-specific peptibody using GLP-1 analogs) DSP Team manager Project leader for GX-F7 (Factor VII-hyFc) and metabolic disease (bi-specific peptibody using GLP-1 analogs)